Stocks Health care HIND
NASDAQ · Health careVyome Holdings, Inc (HIND)
Vyome Holdings, Inc brought in -$2M of revenue over the twelve months to June 30, 2026, down 130.6% from a year earlier. It posted a net loss of $11.3M. At June 30, 2026 it held $7.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What Vyome Holdings, Inc does
Vyome Holdings, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker HIND.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $319.7K | -$10.3M | -$4.86 | n/a |
| 2024 | $8M | -$1.4M | -$6,001.39 | n/a |
| 2023 | $8.7M | -$11.4M | -$48,110.93 | -$17M |
| 2022 | $11.2M | -$46.2M | -$2,743,078.46 | -$22M |
| 2021 | $13.6M | -$63.1M | -$7,278,855.68 | -$15.7M |
| 2020 | $11.3M | -$21.6M | -$8,064,972.09 | -$8.7M |
Where HIND ranks in Health care
Latest SEC filings
What Vyome Holdings, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 28, 2026
- August 25, 2026
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 98% to $27K versus the same quarter last year; diluted EPS -$0.10 versus -$799.90.
- May 29, 2026
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 97% to $31.6K versus the same quarter last year; diluted EPS -$0.15 versus -$761.59.
- April 29, 2026
- March 31, 2026Proxy statement DEF 14A
- March 20, 2026Preliminary proxy statement PRE 14A
- March 18, 2026Annual report 10-K · period to December 31, 2025Revenue fell 96% to $319.7K versus the prior year; diluted EPS -$4.86 versus -$6,001.39.
- February 25, 2026
Insider trades
What the people running Vyome Holdings, Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns HIND
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bigger Michael13G, passive with 6 related filers | 9.68% | February 21, 2025 |
| FirstFire Global Opportunities Fund LLC13G, passive | 6.1% | February 24, 2025 |
| Leonite Fund I, LP13G, passive with 1 related filers | 6.1% | February 24, 2025 |
Largest institutional holders
Insiders
Questions about HIND
What does Vyome Holdings, Inc do?
Vyome Holdings, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker HIND.
Is Vyome Holdings, Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $11.3M.
How much revenue does Vyome Holdings, Inc make?
Over the twelve months to June 30, 2026 Vyome Holdings, Inc reported revenue of -$2M. That is 130.6% less than a year earlier.
When did Vyome Holdings, Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 3, 2026.
Similar companies
Compare HIND with
Follow HIND
Get an email when Vyome Holdings, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow HIND: get an email when it filesWhere the numbers come from
Financial figures are the values Vyome Holdings, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.